---
title: "Bpifrance Participations, Innate Pharma board director, purchases EUR 3 million of Innate Pharma shares"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295958260.md"
description: "Innate Pharma announced that Bpifrance Participations, a board member represented by Olivier Martinez, purchased 1,764,705 shares at EUR 1.7 per share, totaling approximately EUR 3 million. The transaction occurred outside a trading venue."
datetime: "2026-08-14T16:33:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295958260.md)
  - [en](https://longbridge.com/en/news/295958260.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295958260.md)
generator: "portal-rs"
---

# Bpifrance Participations, Innate Pharma board director, purchases EUR 3 million of Innate Pharma shares

-   Innate Pharma announced Bpifrance Participations, a board member represented by Olivier Martinez, subscribed for 1,764,705 shares at EUR 1.7. \* The purchase took place outside a trading venue. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innate Pharma SA published the original content used to generate this news brief on August 14, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [IPHA.US](https://longbridge.com/en/quote/IPHA.US.md)

## Related News & Research

- [Innate Pharma prices private placement of new shares at EUR 1.7 each](https://longbridge.com/en/news/296394400.md)
- [Innate Pharma Secures €30M, Extends Cash Runway Into 2028](https://longbridge.com/en/news/295966041.md)
- [Bpifrance crosses 10% voting rights threshold in Exosens, holds 7.22% stake](https://longbridge.com/en/news/296815356.md)
- [LSL Pharma Group Inc. reports Q2 results](https://longbridge.com/en/news/296953883.md)
- [Abionyx Pharma sees IRIS Pharma 2026 revenue broadly stable vs 2025](https://longbridge.com/en/news/297214105.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**